Drug intelligence / Profile preview

PTI-103

Development stage: Preclinical
Lead developer: Postsurgical Therapeutics
Modality: Hydrogel Systems → Drug Delivery Systems, Small Molecules
Administration: Local

Overview

PTI-103 is a preclinical-stage drug delivery system developed by Postsurgical Therapeutics for the local, postsurgical targeted therapy of cancer. It utilizes a proprietary poly(lactic-co-glycolic acid) (PLGA) platform, which can be formulated as either microspheres or an in-situ gel. The system is designed for implantation or local delivery at the site of tumor resection to provide sustained release of anticancer agents, aiming to eliminate residual cancer cells and prevent local recurrence. As of the latest reports, PTI-103 has completed non-GLP efficacy animal testing.

Beyond the preview

Go deeper on PTI-103.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PTI-103.

Explore the full profile